{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Pancreas&page=14", "query": { "condition": "Metastatic Adenocarcinoma of the Pancreas", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 429, "total_pages": 43, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Pancreas&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Pancreas&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T13:06:21.167Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07377045", "title": "Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma Metastatic" ], "interventions": [ { "name": "OMTX705", "type": "DRUG" }, { "name": "Nab-paclitaxel + Gemcitabine", "type": "DRUG" }, { "name": "Tislelizumab (i.v. 200mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncomatryx Biopharma S.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2025-10-28", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07377045" }, { "nct_id": "NCT03849469", "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Cervical Carcinoma", "Pancreatic Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced or Metastatic Solid Tumors", "Prostate Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Intrahepatic Cholangiocarcinoma", "Squamous Cell Anal Cancer", "Squamous Cell Penile Carcinoma", "Squamous Cell Vulvar Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma" ], "interventions": [ { "name": "XmAb®22841", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (Keytruda®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-05-29", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 28, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849469" }, { "nct_id": "NCT02671890", "title": "Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Refractory Malignant Solid Neoplasm", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Disulfiram", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2016-02-25", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Thief River Falls, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Thief River Falls", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02671890" }, { "nct_id": "NCT00059982", "title": "Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "perifosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-07", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 10, "location_summary": "Urbana, Illinois • South Bend, Indiana • Des Moines, Iowa + 7 more", "locations": [ { "city": "Urbana", "state": "Illinois" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Duluth", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00059982" }, { "nct_id": "NCT07259317", "title": "Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma", "Carcinoma, Pancreatic Ductal" ], "interventions": [ { "name": "Relacorilant", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-01-27", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07259317" }, { "nct_id": "NCT02132468", "title": "A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "fosbretabulin tromethamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mateon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2014-09", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 5, "location_summary": "Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "The Bronx", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02132468" }, { "nct_id": "NCT04657068", "title": "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "Metastatic Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Acinar Cell Carcinoma" ], "interventions": [ { "name": "ART0380", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artios Pharma Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 542, "start_date": "2021-01-27", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04657068" }, { "nct_id": "NCT06451497", "title": "This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Pancreas Adenocarcinoma", "Biliary Tract Cancer", "Prostate Cancer", "Urothelial Carcinoma", "Colorectal Cancer", "Triple Negative Breast Cancer", "High Grade Ovarian Serous Adenocarcinoma", "Diffuse Large B Cell Lymphoma", "Renal Cell Cancer Metastatic" ], "interventions": [ { "name": "ZM008", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Zumutor Biologics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-05-22", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Austin, TX 78758", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06451497" }, { "nct_id": "NCT07089940", "title": "OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Locally Advanced Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Myc Inhibitor OMO-103", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2026-01-27", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07089940" }, { "nct_id": "NCT03193190", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "PEGPH20", "type": "DRUG" }, { "name": "BL-8040", "type": "DRUG" }, { "name": "Selicrelumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "RO6874281", "type": "DRUG" }, { "name": "AB928", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 341, "start_date": "2017-07-05", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-15T13:06:21.167Z", "location_count": 12, "location_summary": "Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03193190" } ] }